JP2002538814A - Ｈｉｖ感染の予防および治療のための新規キメラタンパク質 - Google Patents

Ｈｉｖ感染の予防および治療のための新規キメラタンパク質

Info

Publication number
JP2002538814A
JP2002538814A JP2000605633A JP2000605633A JP2002538814A JP 2002538814 A JP2002538814 A JP 2002538814A JP 2000605633 A JP2000605633 A JP 2000605633A JP 2000605633 A JP2000605633 A JP 2000605633A JP 2002538814 A JP2002538814 A JP 2002538814A
Authority
JP
Japan
Prior art keywords
protein
binding
binding domain
hiv
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2000605633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002538814A5 (https=
Inventor
エドワード エー． バーガー
カスティロ クリスティ デル
Original Assignee
ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ filed Critical ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ
Publication of JP2002538814A publication Critical patent/JP2002538814A/ja
Publication of JP2002538814A5 publication Critical patent/JP2002538814A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000605633A 1999-03-16 2000-03-16 Ｈｉｖ感染の予防および治療のための新規キメラタンパク質 Ceased JP2002538814A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12468199P 1999-03-16 1999-03-16
US60/124,681 1999-03-16
PCT/US2000/006946 WO2000055207A1 (en) 1999-03-16 2000-03-16 A novel chimeric protein for prevention and treatment of hiv infection

Publications (2)

Publication Number Publication Date
JP2002538814A true JP2002538814A (ja) 2002-11-19
JP2002538814A5 JP2002538814A5 (https=) 2007-04-12

Family

ID=22416252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000605633A Ceased JP2002538814A (ja) 1999-03-16 2000-03-16 Ｈｉｖ感染の予防および治療のための新規キメラタンパク質

Country Status (8)

Country Link
EP (1) EP1161455B1 (https=)
JP (1) JP2002538814A (https=)
AT (1) ATE407146T1 (https=)
AU (1) AU765218B2 (https=)
CA (1) CA2361292C (https=)
DE (1) DE60040136D1 (https=)
ES (1) ES2313886T3 (https=)
WO (1) WO2000055207A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017125035A (ja) * 2003-05-16 2017-07-20 アコーダ セラピューティクス、インク． Ｃｎｓを治療するための融合タンパク質

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925966D0 (en) 1999-11-02 1999-12-29 Petrik Juraj Threapeutic vaccines against variable viruses and other targets
IL141023A0 (en) * 2001-01-22 2002-02-10 Gavish Galilee Bio Appl Ltd Recombinant polypeptides for effective hiv neutralization
DK1390535T3 (da) * 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
ATE481109T1 (de) 2001-10-16 2010-10-15 Us Gov Health & Human Serv Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden
US7368114B2 (en) 2001-10-25 2008-05-06 The United States Of America As Represented By The Department Of Health And Human Services Fusion protein including of CD4
US7566451B2 (en) 2002-05-06 2009-07-28 The United States Of America As Represented By The Department Of Health And Human Services Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
ES2319838B1 (es) * 2006-09-29 2010-02-11 Consejo Superior Investig. Cientificas Uso de inhibidores de la actividad de la proteina filamina a, para la elaboracion de composiciones farmaceuticas, compuestos inhibidores de dicha actividad, composiciones farmaceuticas y sus aplicaciones terapeuticas y procedimiento identificacion de dichos compuestos inhibidores.
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
AU2016271124C1 (en) * 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
MX2022000896A (es) * 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047318A1 (en) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection
WO1998044132A1 (en) * 1997-03-28 1998-10-08 New York University VIRAL VECTORS HAVING CHIMERIC ENVELOPE PROTEINS CONTAINING THE IgG-BINDING DOMAIN OF PROTEIN A

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047318A1 (en) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection
WO1998044132A1 (en) * 1997-03-28 1998-10-08 New York University VIRAL VECTORS HAVING CHIMERIC ENVELOPE PROTEINS CONTAINING THE IgG-BINDING DOMAIN OF PROTEIN A

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017125035A (ja) * 2003-05-16 2017-07-20 アコーダ セラピューティクス、インク． Ｃｎｓを治療するための融合タンパク質
JP2020111578A (ja) * 2003-05-16 2020-07-27 アコーダ セラピューティクス、インク． Ｃｎｓを治療するための融合タンパク質

Also Published As

Publication number Publication date
CA2361292A1 (en) 2000-09-21
ES2313886T3 (es) 2009-03-16
EP1161455B1 (en) 2008-09-03
EP1161455A1 (en) 2001-12-12
ATE407146T1 (de) 2008-09-15
AU765218B2 (en) 2003-09-11
CA2361292C (en) 2012-05-29
WO2000055207A1 (en) 2000-09-21
DE60040136D1 (de) 2008-10-16
AU3889600A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
Lasky et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor
Boyd et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development
Wyatt et al. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region
US20130189264A1 (en) A novel chimeric protein for prevention and treatment of hiv infection
US6042836A (en) HIV envelope polypeptides
CN113173995B (zh) 一种结合冠状病毒的双特异性抗体
NZ230855A (en) Principal neutralising domain of hiv variant, dna, vaccine, assay, antibodies and treatment
CA2221571A1 (en) Multispecific chimeric receptors
IL204302A (en) Polynucleotide sequence comprising a nucleic acid encoding a chimeric polypeptide comprising a virus coat and viral receptor, expression vector and method for identifying an agent
JPH05505112A (ja) Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
WO1994020632A1 (fr) Anticorps monoclonal dirige contre le vih
IL127701A (en) HIV gp 120 ENVELOPE POLYPEPTIDES, VACCINE AND METHODS FOR THEIR PREPARATION
Shotton et al. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein
JPH10506008A (ja) ＨＩＶ−１ Ｖｐｒ 融合分子に基づいたＨＩＶビリオン中へのタンパク質ターゲッティング
EP1161455B1 (en) A novel chimeric protein for prevention and treatment of hiv infection
US7825085B2 (en) Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells
GB2196634A (en) Monoclonal antibodies to HIV and related peptides
US6121021A (en) Constitutive expression of non-infectious HIV-like particles
JP2004522401A (ja) ワクチンおよび治療薬としてのｃｄ４非依存性のｈｉｖエンベロープタンパク質
US20240285790A1 (en) Antibody-cd4 conjugates and methods of using the same
CZ239694A3 (en) Recombinant human antibody against hiv, cassette for expression, host cell and a pharmaceutical preparation against hiv
CN114907490B (zh) 强效双功能hiv进入抑制剂及其应用
CN115160435B (zh) 一种双特异性抗hiv-1抗体
Galea et al. A novel epitope R7V common to all HIV-1 isolates is recognized by neutralizing IgG found in HIV-infected patients and immunized rabbits
Crise Transport, modification, and intracellular interactions of CD4

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100531

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110107

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110309

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20110725